ONITT: A phase I study of nanoliposomal irinotecan with talazoparib or temozolomide in children and young adults with recurrent or refractory solid tumors. Promoting Resilience in Stress Management ...
Tumor agnostic efficacy of selpercatinib in patients with RET fusion+ solid tumors: A global, multicenter, registrational trial update (LIBRETTO-001). This is an ASCO Meeting Abstract from the 2022 ...
BOSTON, Jan. 6, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology & inflammation (I&I), today ...